Abstract: Novel compounds of the pyridinium series useful for the management of diabetes and aging-related vascular and neurovascular complications, including kidney disease, nerve damage, atherosclerosis, retinopathy, inflammatory disorders, immunological disorders, oxidative stress, dermatological disorders and discoloration of teeth, by breaking preformed AGE, of the general formula I, or pharmaceutically acceptable salts thereof, 1

Abstract: The invention discloses a process for the preparation of a pyridine derivative namely 5-{4-2(N-methyl-N(2-pyridyl)amino ethoxy]benzyl]thiazolidine-2,4-dione maleate comprising the steps of: (a) reacting 2-chloropyridine with 2-(N-methyl amino)ethanol; (b) coupling 2-(N-methyl-N-(2-pyridyl) amino)ethanol) obtained in step (a) and 4-fluorobenzaldehyde in an aprotic polar solvent with an alkali metal hydroxide or an alkali metal alkoxide as base. (c) isolating the product of the coupling reaction viz 4-[2-(N-methyl-N-(2-pyridyl) amino) ethoxy]benzaldehyde; (d) converting said isolated benzaldehyde compound of step (c) into 5-[4-[2-N-methyl-N-(2-pyridyl) amino)ethoxy]benzyl]thiazolidine-2,4-dione in a known manner and (e) converting said thiazolidine-2,4-dione compound obtained in step (d) into a pharmaceutically acceptable maleate salt.

Abstract: The invention discloses novel compounds of the pyridinium series useful for the management of diabetes and aging-related vascular complications, including kidney disease, nerve damage, atherosclerosis, retinopathy, dermatological disorders and discoloration of teeth, by breaking preformed AGE, of the general formula I, or pharmaceutically acceptable salts thereof, wherein, R1, R2, R3, X and m are as defined in the specification.

Abstract: The invention discloses a process for the preparation of a pyridine derivative namely 5-{4-2(N-methyl-N(2-pyridyl) amino ethoxy]benzyl]thiazolidine-2,4-dione maleate comprising the steps of:

Abstract: The invention discloses a new class of compounds particularly pyridinium derivatives which have been found to exhibit triple function of a free radical scavenger (antioxidant), AGE breaker and AGE inhibitor, and cosmetic composition comprising these compounds contained in a cosmetically acceptable carrier. The invention also discloses a method of cosmetic application by applying such composition. The invention further discloses a pharmaceutical composition comprising said compounds useful in scavenging free radicals from the body cells of a mammal, a method of scavenging free radicals from the body cells of a mammal and a method of treating of diseases caused by accumulation of free radicals in the body cells of a mammal by administering a composition made with the compounds of the invention. The invention also discloses composition and method for inhibiting AGE in a mammal by using the compounds of the invention.

Abstract: The invention discloses a safer Antiarrhythmic drug with controlled Beta Adrenergic activity which comprises a combination of dextro- and laevo-rotatory isomers of sotalol as active ingredients, pharmaceutical compositions with said combination as active ingredients and its preparation and use of the said combination in the treatment of cardiac ailments in mammals including human beings.

Abstract: The invention discloses a novel compound of the benzofuroxan series used for cardiovascular disorders represented by the general formula (I) and pharmaceutically acceptable salts thereof wherein: R is —O—(CH2)n-X-R′; n=1 to 6; X is —NHC(O)—, or oxygen; R′ is lower alkyl (C1-C8), aromatic, heteroaromatic, substituted or unsubstituted saturated heterocyclic ring with one or two hetero atoms such as nitrogen or oxygen wherein substitution is with lower alkyl; or R is selected from wherein R″ is hydrogen, nitro, lower alkyl or—C(O)—R′″ wherein R′″ is hydrogen, lower alkyl or aryl. The invention also discloses process for the preparation of compounds of general formula I.

Abstract: The invention discloses use of a compound of the benzofuroxan series for treatment of cardiovascular disorders represented by the general formula (I) and pharmaceutically acceptable salts thereof wherein: R is halogen, acetoxy, —X—R′, —C(O)NR″R′″, or —C(O)Cl; X is oxygen, sulfur, —C(O)—, or —C(O)O—; R′ is hydrogen, straight chain or branched lower alkyl (C1-C8); R″ and R′″ are independently hydrogen, straight chain or branched lower alkyl (C1-C8) or R″ and R′″ are linked together with or without a heteroatom selected from the group consisting of oxygen and nitrogen wherein substitution on nitrogen is with hydrogen or lower alkyl. The invention further discloses pharmaceutical compositions containing compounds of general formula I as active ingredients.

Abstract: There is disclosed an improved process for the preparation of 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine which process comprises the step of reacting 2,3-dichlorobenzoylchloride with cuprous cyanide in presence of acetonitrile and a cosolvent to produce dichlorobenzoyl cyanide, said dichlorobenzoyl cyanide is reacted with aminoguanidine bicarbonate to produce an intermediate product, which is cyclized in presence of aqueous potassium hydroxide to produce 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine.